Clearmind licenses psychedelic compounds for mental disorders
Pharmaceutical Technology
APRIL 18, 2024
Clearmind Medicine has entered into a licensing agreement with Yissum to develop Generation 3.0 psychedelic compounds for mental disorders.
Merck agrees to license COVID-19 pill widely through pact with patent group
Bio Pharma Dive
OCTOBER 27, 2021
The deal with the Medicines Patent Pool is meant to increase access in lower-income countries to molnupiravir, an experimental drug that could become the first oral treatment for COVID-19.
Licensing 
321
321 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer buys into Biohaven's fast-selling migraine medicine
Bio Pharma Dive
NOVEMBER 9, 2021
rights to rimegepant — a sizable licensing deal, though not the buyout that some of the biotech's investors appeared to be hoping for. The pharmaceutical giant will pay Biohaven $500 million for ex-U.S.
Medicine 269
269 
IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations
Bio Pharma Dive
AUGUST 2, 2022
Founded by serial entrepreneur Alexis Borisy, the company comes equipped with two experimental medicines it licensed from Merck KGaA and Blueprint Medicines.
Licensing 306
306 
How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing
Drug Patent Watch
DECEMBER 12, 2024
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.
Licensing 96
96 
Rebounding from setbacks, Sanofi reveals promising data for hemophilia drug
Bio Pharma Dive
DECEMBER 14, 2021
Fitusiran, which Sanofi licensed from Alnylam, could finally get to market after trial delays and safety concerns slowed its progress. But gene therapies and other new medicines might provide competition.
Gene Therapy 323
323 
Editas, changing course again, looks to partner lead CRISPR therapy
Bio Pharma Dive
OCTOBER 22, 2024
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.
Gene Editing 286
286 
Novartis wagers billions of dollars on PTC Huntington’s drug
Bio Pharma Dive
DECEMBER 2, 2024
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
Licensing 278
278 
Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin
Pharmaceutical Technology
MARCH 17, 2023
Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health.
Hormones 263
263 
MSD secures worldwide license for LaNova’s LM-299
Pharmaceutical Technology
NOVEMBER 15, 2024
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular endothelial growth factor (VEGF) bispecific antibody, LM-299.
Licensing 130
130 
Verdiva starts up with $411M and a portfolio of obesity drugs from China
Bio Pharma Dive
JANUARY 9, 2025
The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.
Licensing 254
254 
EQRx builds cancer drug pipeline as plans to challenge big pharma take shape
Bio Pharma Dive
OCTOBER 27, 2020
The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.
Licensing 269
269 
Benefits of Drug Patent Licensing Agreements
Drug Patent Watch
JULY 30, 2024
The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…
Licensing 105
105 
Lilly partners with AI specialist Insitro to develop metabolic medicines
Bio Pharma Dive
OCTOBER 9, 2024
The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.
Medicine 161
161 
STAT+: ‘Stuck in a rut’: As debate flares over access to medicines, the future of voluntary licensing is up in the air
STAT News
JANUARY 5, 2023
Last fall, Novartis agreed to license a best-selling cancer drug so that generic companies could make copies for distribution to 44 low- and middle-income nations, marking the first time a voluntary license was arranged for a cancer medicine. ANNECY, FRANCE — At first blush, the deal was hailed as a breakthrough.
Licensing 116
116 
Gemini enters business combination deal with Disc Medicine
Pharmaceutical Technology
AUGUST 11, 2022
Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US. Last year, Disc in-licensed bitopertin from Roche.
Medicine 147
147 
Shionogi and MPP enter Covid-19 antiviral licensing deal
Pharmaceutical Technology
OCTOBER 4, 2022
Shionogi & Co and the United Nations (UN)-backed public health organisation Medicines Patent Pool (MPP) have entered a voluntary licence agreement for the former’s oral Covid-19 antiviral candidate ensitrelvir fumaric acid (S-217622).
Licensing 147
147 
Melinta and Cidara sign licensing deal for rezafungin
Pharmaceutical Technology
JULY 28, 2022
“By leveraging our expansive commercial infrastructure, we will provide the resources needed to optimise the commercialisation of rezafungin and ensure patient access to this life-saving medicine in the US. “We The post Melinta and Cidara sign licensing deal for rezafungin appeared first on Pharmaceutical Technology.
Licensing 147
147 
UniQure nabs another gene therapy for ALS
Bio Pharma Dive
JANUARY 31, 2023
For $10 million up front, UniQure has licensed rights to its second experimental treatment for the condition, a medicine from startup Apic Bio that should enter human testing later this year.
Gene Therapy 215
215 
Moderna and Generation Bio partner for genetic medicines development
Pharmaceutical Technology
MARCH 24, 2023
Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. Moderna’s biological and technical expertise will be combined with core technologies of the non-viral genetic medicine platform from Generation Bio.
Genetics 130
130 
Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK
Pharma Mirror
APRIL 18, 2023
Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
Licensing 130
130 
Royalty Pharma pays startup $525M for stake in Sanofi MS drug
Bio Pharma Dive
MAY 9, 2024
The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.
Licensing 183
183 
Exelixis licenses AI-designed cancer drug from Insilico Medicine
Outsourcing Pharma
SEPTEMBER 14, 2023
Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.
Medicine 93
93 
Takeda signs licensing agreement with HUTCHMED for fruquintinib
Pharmaceutical Technology
JANUARY 23, 2023
“We look forward to utilising our development and commercial capabilities to expand the potential of this innovative medicine to patients beyond China. “We We have a strong track record of working with companies that share our focus on bringing transformative medicines to patients around the globe who need them.”
Licensing 130
130 
Sangamo’s cell therapy receives EC orphan medicinal product designation
Pharmaceutical Technology
JULY 22, 2022
Sangamo Therapeutics has received orphan medicinal product designation (OMPD) from the European Commission (EC) for its Investigational autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy, TX200, for solid organ transplantation.
Medicine 130
130 
Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.
Bio Pharma Dive
JUNE 18, 2024
With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.
Licensing 169
169 
3BP and Novartis strike licensing agreement for FAP-targeting peptide technology
Pharmaceutical Technology
APRIL 25, 2023
German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. 3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments.
Licensing 130
130 
Bio-Thera and Biomm enter licensing deal for ustekinumab biosimilar
Pharmaceutical Technology
JUNE 19, 2023
Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. It plans to seek regulatory approval from the European Medicines Agency, the China National Medical Products Administration and the US Food and Drug Administration.
Licensing 130
130 
Neurocrine scores surprise win with depression drug
Bio Pharma Dive
APRIL 23, 2024
Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.
Licensing 161
161 
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
Bio Pharma Dive
JUNE 21, 2024
A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.
Licensing 161
161 
Ayush ministry informs HC that it has instructed drug regulators against use of Unani label for Ayurveda drug
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 21, 2023
The Union Ministry of Ayush has submitted in the Delhi High Court that it has instructed the licensing authority for the Ayush systems of medicines in all the States and Union Territories that they should ensure that the labelling and naming of the products for the Ayurvedic and Unani drugs should be as per the […]
Regulation 188
188 
Centre puts onus on SLAs to take action against e-pharmacies for violation of D&C Act and Rules
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 23, 2023
With the chemists and druggists across the country opposing the sale of drugs through online, the Central government is taking a stand that the sale of medicines should be strictly under the provisions of the existing regulations and the State Licensing Authorities (SLAs) are legally empowered to act against violation of the legal provisions.
Pharmacy 188
188 
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
Bio Pharma Dive
DECEMBER 18, 2024
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
Licensing 152
152 
STAT+: Novartis agrees to license a best-selling cancer drug to dozens of low- and middle-income countries
STAT News
OCTOBER 20, 2022
Amid a push to widen access to medicines to poor countries, Novartis has reached an agreement to license one of its best-selling cancer treatments so that generic manufacturers can produce copies for distribution to 44 low- and middle-income nations. Continue to STAT+ to read the full story…
Licensing 98
98 
STAT+: A ViiV deal to license its HIV prevention shot to poor countries runs into criticism
STAT News
JULY 28, 2022
In a much ballyhooed move, ViiV Healthcare finalized a deal to license its long-acting injectable HIV prevention shot to the Medicines Patent Pool so that generic companies can make and distribute lower-cost versions to low- and middle-income countries.
Licensing 98
98 
EC approves Novartis’ Tabrecta for non-small cell lung cancer
Pharmaceutical Technology
JUNE 23, 2022
It was discovered by Incyte and licensed to Novartis in 2009. The latest development comes after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) provided a positive opinion in April this year. A kinase inhibitor, Tabrecta acts on MET.
Medicine 263
263 
GSK pays $90M to gain access to Scynexis antifungal
Bio Pharma Dive
MARCH 30, 2023
The licensing deal for the FDA-approved medicine, Brexafemme, includes milestone payments that could add up to $503 million.
FDA Approval 152
152 
EC announces EU pharma reform that cuts market exclusivity
Pharmaceutical Technology
APRIL 27, 2023
The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity. However, the reform has its share of critics. Applications will now be digitised.
Marketing 264
264 
Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO
XTalks
DECEMBER 4, 2024
In the Asia-Pacific market, Jupiter has negotiated partnerships with companies such as Sichuan Kelun and Tianjin Pharmaceuticals, focusing on Jotrol’s integration into traditional Chinese medicine frameworks. International patents valid until 2036 further strengthen its global positioning.
Bioavailability 111
111 
Let's personalize your content